Ga-68 DOTA-NOC Uptake in the Pancreas
- 1 January 2012
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Clinical Nuclear Medicine
- Vol. 37 (1), 57-62
- https://doi.org/10.1097/rlu.0b013e3182393404
Abstract
Objective: Gallium-68 (Ga-68) DOTA-1-NaI3-octreotide (DOTA-NOC) positron emission tomography (PET)/computed tomography (CT) is increasingly used for neuroendocrine tumors (NETs), often found primarily in the pancreas. However, physiologic uptake of DOTA-NOC has been described in the uncinate process of the pancreas. We studied DOTA-NOC uptake in this organ. Materials and Methods: Ninety-six patients underwent 103 DOTA-NOC scans, with pathology-proven pancreatic NET (n = 40) and nonpancreatic NET or biochemical suspicion of NET (n = 63). Results: DOTA-NOC uptake was detected in 35 documented pancreatic tumor sites (SUV: 5.5–165; mean: 25.7 ± 28.8; median: 17.8). Among 63 cases without previous known pathology, uptake was suspicious for tumor in 24 sites (SUV: 4.7–35; mean 16.3 ± 8.0; median: 14.1), and in 38 sites, it was judged as physiological, generally lower relative to adjacent structures (SUV: 2.2–12.6; mean: 6.6 ± 2.2; median: 6.2). In 24 scans with suspected tumor and in 37 of 38 scans with physiological uptake, diagnostic computed tomography or magnetic resonance imaging or endoscopic ultrasonography failed to detect tumor. Conclusions: Pancreatic DOTA-NOC uptake must be interpreted with caution, and further studies are required.Keywords
This publication has 25 references indexed in Scilit:
- Non-functional Neuroendocrine Carcinoma of the Pancreas: Incidence, Tumor Biology, and Outcomes in 2,158 PatientsJournal of Gastrointestinal Surgery, 2010
- Diagnosis of pancreatic neoplasia with EUS and FNA: a report of accuracyGastrointestinal Endoscopy, 2009
- 68Ga-DOTA-Tyr3-Octreotide PET for Assessing Response to Somatostatin-Receptor–Mediated Radionuclide TherapyJournal of Nuclear Medicine, 2009
- Gastroenteropancreatic neuroendocrine tumoursThe Lancet Oncology, 2008
- Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumoursEuropean Journal of Nuclear Medicine and Molecular Imaging, 2007
- 68Ga-DOTATATE PET in neuroectodermal tumours: First experienceNuclear Medicine Communications, 2007
- 68Ga-DOTA-Tyr3-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CTJournal of Nuclear Medicine, 2007
- Nuclear medicine in the detection and management of pancreatic islet-cell tumoursBest Practice & Research Clinical Endocrinology & Metabolism, 2005
- DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometalsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2003
- Endoscopic ultrasound is highly accurate and directs management in patients with neuroendocrine tumors of the pancreasThe American Journal of Gastroenterology, 2000